Literature DB >> 23167931

Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population.

Yan-bin Chen1, Chuan-yong Mu, Cheng Chen, Jian-An Huang.   

Abstract

AIM: To evaluate the correlation between a polymorphism of PD-L1 gene and the susceptibility of non-small cell lung cancer (NSCLC) in a Chinese population.
METHODS: A total of 293 Chinese patients with NSCLC and 293 age and sex matched controls of the same ethnic origin were enrolled in this study. A/C polymorphism at position 8923 in intron 4 of PD-L1 gene was typed using the polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP). The interactions between A/C genotype, allele frequency and NSCLC susceptibility were analyzed.
RESULTS: The A/C genotype frequencies were significantly different between NSCLC patients and controls. The AC and CC frequencies were higher in NSCLC patients than in controls (16.4 vs 8.9%, 1.0 vs 0.3%, respectively). The C-allele frequency was higher in NSCLC patients than in controls (9.2 vs 4.8%). Significant differences in the A and C allele frequencies were noted between the two groups (χ(2) = 8.864, P = 0.003). More risk of NSCLC was found in individuals carrying the C allele than in those carrying the A allele (OR = 2.203; 95% CI 1.262-3.242). In both light smokers (≤20 pack-years) and heavy smokers (>20 pack-years), individuals carrying the C-allele had more risk of NSCLC than those carrying the A-allele (light smokers OR = 1.847, 95% CI 1.001-3.409; heavy smokers OR = 3.252, 95% CI 1.196-8.845, respectively).
CONCLUSION: An A/C polymorphism at position 8923 in the PD-L1 gene is associated with NSCLC susceptibility. The PD-L1 polymorphism plays a role in NSCLC, especially in patients with the C-allele.
© 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  PD-L1 gene; non-small cell lung cancer; single nucleotide polymorphism; susceptibility

Mesh:

Substances:

Year:  2012        PMID: 23167931     DOI: 10.1111/ajco.12037

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  10 in total

1.  Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.

Authors:  Yuan Ma; Xiuchun Liu; Jingyan Zhu; Wanhu Li; Liangjun Guo; Xiao Han; Bao Song; Sensen Cheng; Liu Jie
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  A meta-analysis of the relationship between glutathione S-transferase T1 null/presence gene polymorphism and the risk of lung cancer including 31802 subjects.

Authors:  Hua-Fu Zhou; Xu Feng; Bao-Shi Zheng; Jun Qian; Wei He
Journal:  Mol Biol Rep       Date:  2013-09-26       Impact factor: 2.316

Review 3.  PD-1 and cancer: molecular mechanisms and polymorphisms.

Authors:  Arash Salmaninejad; Vahid Khoramshahi; Alireza Azani; Ehsan Soltaninejad; Saeed Aslani; Mohammad Reza Zamani; Masoud Zal; Abolfazl Nesaei; Sayed Mostafa Hosseini
Journal:  Immunogenetics       Date:  2017-06-22       Impact factor: 3.330

4.  Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies.

Authors:  Mohammad Hashemi; Shima Karami; Sahel Sarabandi; Abdolkarim Moazeni-Roodi; Andrzej Małecki; Saeid Ghavami; Emilia Wiechec
Journal:  Cancers (Basel)       Date:  2019-08-10       Impact factor: 6.639

Review 5.  Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.

Authors:  Marta Wagner; Monika Jasek; Lidia Karabon
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

6.  Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma.

Authors:  Anna Grenda; Paweł Krawczyk; Tomasz Kucharczyk; Justyna Błach; Katarzyna Reszka; Izabela Chmielewska; Jarosław Buczkowski; Robert Kieszko; Jan Siwiec; Tomasz Kubiatowski; Aleksandra Bożyk; Kinga Krukowska; Bożena Jarosz; Iwona Paśnik; Juliusz Pankowski; Daria Świniuch; Katarzyna Stencel; Michał Gil; Kinga Lew; Rodryg Ramlau; Aleksandra Szczęsna; Sebastian Fidler; Andrzej Sieracki; Andrzej Każarnowicz; Piotr Serwatowski; Tomasz Grodzki; Janusz Milanowski
Journal:  Oncol Lett       Date:  2021-04-07       Impact factor: 2.967

7.  Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers.

Authors:  Sheng-Kai Liang; Li-Hsin Chien; Gee-Chen Chang; Ying-Huang Tsai; Wu-Chou Su; Yuh-Min Chen; Ming-Shyan Huang; Hsien-Chih Lin; Wen-Tsen Fang; Hsiao-Han Hung; Shih-Sheng Jiang; Chih-Yi Chen; Kuan-Yu Chen; I-Shou Chang; Chao A Hsiung; Chien-Jen Chen; Pan-Chyr Yang
Journal:  Front Oncol       Date:  2021-09-24       Impact factor: 6.244

8.  PD-L1 rs2890658 Polymorphism Increases Risk for Non-Small-Cell Lung Cancer in Northern China Population Based on Experimental Data and Meta-Analysis.

Authors:  Guigang Wang; Yuehua Dong; Yanjun Yang; Wenjing Zhang; Na Liu; Yulei Wei
Journal:  Contrast Media Mol Imaging       Date:  2022-08-02       Impact factor: 3.009

Review 9.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Authors:  Li Shi; Shaohua Chen; Lijian Yang; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2013-09-30       Impact factor: 17.388

10.  Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.

Authors:  Shima Karami; Hedieh Sattarifard; Mohammad Kiumarsi; Sahel Sarabandi; Mohsen Taheri; Mohammad Hashemi; Gholamreza Bahari; Saeid Ghavami
Journal:  Asian Pac J Cancer Prev       Date:  2020-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.